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Abstract
Commercially available diagnostic test kits for detection of dengue virus (DENV) non-structural protein 1 (NS1) and anti-
DENV IgM were evaluated for their sensitivity and specificity and other performance characteristics by a diagnostic
laboratory network developed by World Health Organization (WHO), the UNICEF/UNDP/World Bank/WHO Special
Programme for Research and Training in Tropical Diseases (TDR) and the Pediatric Dengue Vaccine Initiative (PDVI). Each
network laboratory contributed characterized serum specimens for the panels used in the evaluation. Microplate enzyme-
linked immunosorbent assay (ELISA) and rapid diagnostic test (RDT formats) were represented by the kits. Each ELISA was
evaluated by 2 laboratories and RDTs were evaluated by at least 3 laboratories. The reference tests for IgM anti-DENV were
laboratory developed assays produced by the Armed Forces Research Institute for Medical Science (AFRIMS) and the
Centers for Disease Control and Prevention (CDC), and the NS1 reference test was reverse transcriptase polymerase chain
reaction (RT-PCR). Results were analyzed to determine sensitivity, specificity, inter-laboratory and inter-reader agreement,
lot-to-lot variation and ease-of-use. NS1 ELISA sensitivity was 60–75% and specificity 71–80%; NS1 RDT sensitivity was 38–
71% and specificity 76–80%; the IgM anti-DENV RDTs sensitivity was 30–96%, with a specificity of 86–92%, and IgM anti-
DENV ELISA sensitivity was 96–98% and specificity 78–91%. NS1 tests were generally more sensitive in specimens from the
acute phase of dengue and in primary DENV infection, whereas IgM anti-DENV tests were less sensitive in secondary DENV
infections. The reproducibility of the NS1 RDTs ranged from 92-99% and the IgM anti-DENV RDTs from 88–94%.
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Introduction
Dengue is a major public health problem with more than 2.5
billion people at risk for DENV infection and an estimated 96
million cases occur annually in over 100 tropical and sub-tropical
countries [1–3]. Infection with each of the four DENV (DENV
serotypes 1–4) is capable of causing dengue fever as well as severe
dengue. Currently there are no vaccines or drugs available to
prevent or treat dengue. However, early laboratory diagnosis can
ensure timely initiation of appropriate clinical management or
anticipatory guidance in the outpatient setting. Accurate diagnosis
of dengue is an important component of public health surveillance
since clinical diagnosis does not differentiate dengue from other
diseases that present with dengue-like signs and symptoms (e.g.,
malaria, leptospirosis, measles, influenza, Japanese encephalitis
(JEV), West Nile fever (WNV), yellow fever virus (YFV)). Hence,
there is the global need for accurate dengue diagnostics.
Timely and accurate laboratory diagnosis of dengue performed
on a single serum specimen must rely on detection of DENV RNA
or NS1 antigen during the period from fever onset until 5–6 days
later, or detection of anti-DENV IgM beginning 3–5 days after
fever onset until 6 weeks later [4–6]. DENV can be detected by
virus isolation, molecular amplification of DENV RNA by RT-
PCR and immunoassay to detect DENV NS1 antigen. As a
diagnostic technique, virus isolation is not practical since it
requires cell culture facilities, has a long turn-around time and has
lower sensitivity compared to molecular or immunoassay methods
[7]. In low resource settings, use of molecular tests is generally not
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feasible hence NS1 antigen detection may be the best option for
DENV detection. The NS1 test appears to have adequate
sensitivity and specificity when compared to RT-PCR and virus
isolation across DENV serotypes; however, there are differences in
NS1 sensitivity related to patient infection status (i.e., primary
versus secondary DENV infection) [8–14]. Presently, the most
widely used dengue diagnostic test remains the IgM capture anti-
DENV (MAC) ELISA, which lacks adequate sensitivity and
specificity in the acute phase of the illness, a time when most
patients seek medical attention [15,16].
Rapid diagnostic tests (RDTs) for dengue have become
increasing available over the last 5 years because of the need for
point-of-care diagnosis in resource limited settings. However,
previously available RDTs for IgM anti-DENV did not have
acceptable sensitivity compared to anti-DENV IgM microplate
ELISAs which considerably limited their utility [17]. Although
individual NS1 RDTs have been evaluated in a number of studies,
robust estimates of their analytic performance have not been
determined in head-to-head comparisons using specimen panels
that replicate the diagnostic landscape of most dengue endemic
areas.
To determine the analytic performance and reproducibility of
commercially available NS1 antigen tests and newly available IgM
anti-DENV RDTs and microplate ELISAs, a network of
laboratories established by WHO/TDR and the PDVI developed
specimen panels from dengue patients infected with all DENV
serotypes from both the Asian and American continents, and with
primary and secondary DENV infections. In addition, the
evaluation included specimens from patients with other dengue-
like illnesses and other conditions that can produce false-positive
test results.
Methods
The Laboratory Network
The present study was conducted by the seven laboratories of
the WHO/TDR/PDVI dengue diagnostic network that previous-
ly evaluated commercially available IgM anti-DENV diagnostic
tests in 2007 [17]. Laboratories in Asia included: Centre for
Vaccine Development, Mahidol University, Thailand; Hospital for
Tropical Medicine, Cho Quan Hospital, Viet Nam; Institut
Pasteur in Cambodia; and University of Malaya, Malaysia; and in
the Americas: Dengue Branch, CDC, Puerto Rico; Instituto
Medicina Tropical ‘‘Pedro Kouri’’, Cuba; and Instituto Nacional
Enfermedades Virales Humanas ‘‘Dr. Julio I. Maiztegui’’,
Argentina. The laboratories at CDC, Puerto Rico and Mahidol
University, Thailand served as the reference laboratories and
provided specimens for proficiency testing among the laboratories,
assembled and validated the evaluation panels and distributed the
test kits.
Ethics Statement
This study was reviewed by the WHO Ethics Review
Committee and considered exempt. All patient samples used for
this study were de-linked from personal identifiers and renum-
bered with a study identifier.
Study Initiatives
The mission of the Accessible Quality Assured Diagnostics
program within the UNICEF/UNDP/World Bank/WHO Spe-
cial Programme for Research and Training in Tropical Diseases
(WHO/TDR) is to promote and facilitate development, evalua-
tion and deployment of diagnostic tools for the control of the
tropical diseases. PDVI was a product development partnership
established to accelerate development, evaluation and introduction
of dengue vaccines for children in endemic countries.
The previous study by the WHO/TDR/PDVI dengue
diagnostic laboratory network resulted in recommendations to
included three commercially available IgM anti-DENV ELISA
tests in the WHO bulk procurement scheme (WHO report; [17]).
Since this study, a number of tests for detection of NS1 antigen
had become commercially available in addition to a number of
new anti-DENV IgM tests. On 10–12 February 2009 the steering
group and directors of the network laboratories met to plan the
present study to evaluate the analytic performance and operational
characteristics of newly available anti-DENV IgM and NS1
antigen detection tests in microplate ELISA and RDT formats for
the diagnosis of dengue.
Clinical Specimens
Specimen panels were created for anti-DENV IgM and NS1
testing (Table 1 and 2) based on the study design developed by the
steering group with statistical consultation. Panels contained a
sufficient number of true positive and negative specimens to give a
confidence interval (CI) of +5% around the point estimates for test
sensitivity and specificity [18]. Specimens were selected in a way
that achieved geographic representation of the four DENV
serotypes and were obtained from archived clinical samples at
the participating laboratories and were submitted to the reference
laboratories for assembly of the final panels. Case-specimens came
from dengue patients that met the 1997 WHO dengue case
classification and were laboratory confirmed by the presence of
DENV detected by RT-PCR and/or virus isolation. All dengue
cases included in the panels had paired, acute (#5 days post onset
of illness) and convalescent (6–14 days post onset of illness)
specimens. However, the study design was not such that specimens
for the acute and convalescent periods were allocated by specific
days post onset of illness (see Supplemental Table S1), and analysis
had to be performed for results from the aggregate acute and
convalescent time periods. For certain categories in the challenge
panels, serum specimens were purchased from SeraCare Diag-
nostics (West Bridgewater, MA).
Author Summary
Dengue virus (DENV) infection occurs throughout tropical
and sub-tropical regions of the world where dengue is a
major public health problem. Laboratory diagnosis of
dengue with a single serum specimen obtained during the
acute phase of the illness requires tests to detect IgM
antibodies to DENV or the virus genome. A previous
evaluation of available tests for IgM anti-DENV showed
wide variability. The present study examined newly
available commercial tests that detect the virus protein
NS1, as well as new tests for IgM anti-DENV in microplate
or rapid diagnostic test formats. This analytic study used
specimens from laboratory confirmed dengue patients
worldwide, which makes the results widely generalizable.
The study found variability among the microplate ELISAs
for both analytes but some tests performed with sensitivity
and specificity acceptable for routine dengue diagnostics.
The RDT’s for both analytes had variable sensitivity that
could be considered acceptable for routine clinical
diagnostics. There is the need to maintain a network of
dengue reference laboratories to conduct similar evalua-
tions as additional dengue diagnostic tests become
commercially available in order to guide the use for
surveillance, clinical diagnosis and research.
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Table 1. Characteristics of specimens from dengue patients in the panel to evaluate dengue virus (DENV) non-structural protein 1
(NS1) detection kits.
Panel Region Dengue infection* Serotype Acute" Convalescent# Subtotal Total
NS1 Americas Primary D1 4 4
D3 5 5
D4 1 1
Subtotal 10 10 10
Secondary D1 24 24
D2 25 25
D3 17 17
D4 9 9
Subtotal 75 75 75
Asia Primary D1 3 5 8
D3 7 20 27
Subtotal 10 25 35 35
Secondary D1 4 12 16
D2 2 13 15
D3 4 22 26
D4 2 13 15
Subtotal 12 60 72 72
Total 107 85 192 192
*Primary = 1 DENV infection, Secondary $2DENV infections.
"days post onset of fever = 0–5.
#days post onset of fever = 6–14.
doi:10.1371/journal.pntd.0003171.t001
Table 2. Characteristics of specimens from dengue patients included in the panel to evaluate anti-DENV IgM detection kits.
Panel Region Dengue infection* Serotype Acute" Convalescent# Not defined Subtotal Total
IgM America Secondary D1 29 29
D2 26 26
D3 17 17
D4 8 8
Subtotal 80 80 80
Asia Primary D1 8 8
D2 3 3
D3 16 16
DF 1 3 4
DHF 4 4
Subtotal 28 7 35 35
Secondary D1 15 15
D2 10 10
D3 5 17 22
D4 4 19 4 27
Not defined 4 35 39
Subtotal 28 81 4 113 113
Total 56 168 4 228 228
DENV = dengue virus.
*Primary = 1 DENV infection, Secondary $2 DENV infections.
"days post onset of fever = 0–5.
#days post onset of fever = 6–14.
doi:10.1371/journal.pntd.0003171.t002
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The following epidemiological data were available for all case-
specimens: date of onset of symptoms, date of sample collection,
patient age, sex, summary of clinical history and diagnosis, travel
history 12 months prior to the date of specimen collection, and
vaccination history (i.e. YFV, JEV or other flavivirus vaccines).
Case-patient specimens were classified as dengue fever (DF),
dengue hemorrhagic fever (DHF), or dengue shock syndrome
(DSS) based on data from clinical records using the 1997 WHO
case definition.
Lipemic, hemolyzed or bacterially contaminated specimens
were not included in the panels. Only specimens with #2 freeze-
thaw cycles were included, all were heat-inactivated at 56uC for
30 minutes, lyophilized in aliquots, coded by the reference
laboratories, assembled into the respective panels which were
shipped to each evaluation laboratory. Written standard operating
procedures were developed and used by participating laboratories
to assure uniformity in sample handling, storage and testing.
Because some commercial tests can be highly sensitive to storage
and shipping conditions, data on transit time was recorded for
later analysis.
Testing Protocol
Letters requesting study participation were sent to 20 dengue
diagnostic kit manufacturers; seven companies agreed to partic-
ipate and provided the tests shown in Table 3 and supplemental
Table S2 A–D. All kits were shipped by the manufacturers at
ambient temperatures, checked for damage upon arrival and
stored in the specified environment. RDT kits were shipped to
only one of the reference laboratories where they were
subsequently shipped to the evaluation laboratories under
conditions specified by the manufacturer. Microplate ELISAs
were only evaluated by the reference laboratories since the
previous evaluation did not show significant inter-laboratory
differences in results [17]. Delays in shipping or damage were
noted and reported by the evaluation laboratories.
Ten specimens known to be NS1 positive using the Platelia
ELISA (BioRad, Lyon, France) were tested following lyophyliza-
tion, heat inactivation and one freeze-thaw cycle and showed no
change in sensitivity by any of these treatments (data not shown).
Specimens from each panel were tested in duplicate in the same
analytical run to measure within-run precision; inter-run precision
was evaluated by comparing results across evaluation laboratories.
RDTs were tested in duplicates, with two readers evaluating each
result independently. Inter-reader agreement was considered an
important variable since RDTs required subjective judgment. All
testing was conducted with strict adherence to the manufacturer’s
protocol described in the package insert. Each evaluation
laboratory recorded testing data on standardized data sheets,
which were submitted to WHO/TDR for analysis. Information
was also collected from each performing technician regarding the
ease-of-use of these products. This study was initiated in 2011 and
completed within the same year.
The Panels
DENV NS1 panel. This panel consisted of a total of 390
dengue patient serum specimens in 3 sub-panels: 192 dengue
patients who were DENV positive by virus isolation and/or RT-
PCR for DENV RNA, 146 DENV RNA or culture negatives and
52 challenge specimens from other illnesses or conditions that may
result in false positive results to determine the specificity of these
tests (Tables 1 and 4). DENV RNA or culture positive serum
specimens were collected 0–5 days post onset of fever (DPO). All
dengue cases had paired acute (DPO 0–5) and convalescent (DPO
6–14) specimens.
Network laboratories tested a limit of detection panel to ensure
comparable sensitivity of their RT-PCR assay as a reference
standard. The methods of RNA extraction and RT-PCR used in
the network laboratories included: nested RT-PCR by Lanciotti et
al., 1992 [18], real-time RT-PCR methods developed by Laue et
al., 1999 [19] Kong et al., 2006 [20]and Chien et al., 2006 [21].
Network laboratories tested a panel of serially diluted cell culture-
derived DENV RNA to determine the limit of detection of their
RT-PCR assays and ensure comparable testing sensitivity. For
virus isolation, cell culture isolation was performed using an
accepted reference method [22].
DENV positive specimens included patients with primary and
secondary DENV infections and represented all 4 DENV
serotypes. Primary and secondary infections were distinguished
according to criteria established by WHO using hemagglutination-
inhibition assay described by Clark and Casals, 1958 adapted to
96-well microtiter plate [23,24]. This approach was adapted to
IgG ELISA where a primary DENV infection was defined as
evidence of first exposure to DENV based on anti-DENV IgG
seroconversion between and acute and convalescent specimen,
Table 3. Dengue virus NS1 antigen detection and IgM anti-dengue virus tests submitted for evaluation.
Test Type Test Name Company Name
NS1 ELISAs Platelia Dengue NS1 Ag Bio-Rad
Dengue Early ELISA Panbio/Alere
Dengue NS1 Ag ELISA Standard Diagnostics, Inc.
NS1 RDTs Dengue NS1 Ag Strip Bio-Rad
OnSite Dengue Ag Rapid Test CTK Biotech
Dengue Early Rapid Test Panbio/Alere
SD BIOLINE Dengue Duo Standard Diagnostics, Inc.
IgM ELISA DENV-JEV MACE Venture Technologies Sdn Bhd
IgM RDTs Dengue IgG/IgM Rapid Test device Abon Biopharma
OnSite Dengue IgG/IgM Combo CTK Biotech
ImmunoComb II Dengue IgM & IgG Bispot Orgenics/Iverness
SD BIOLINE Dengue Duo Standard Diagnostics, Inc.
doi:10.1371/journal.pntd.0003171.t003
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and a secondary DENV infection was defined as evidence of more
than one DENV infection as determined by anti-DENV IgG
positive titer during the acute phase of disease [25].
This panel also included paired, acute and convalescent
specimens from patients who were DENV RNA and/or virus
isolation positive and anti-DENV IgM negative in the acute phase
specimens but DENV RNA and/or virus isolation negative and
anti-DENV IgM positive in the convalescent specimens. These
specimens were used to determine the duration of NS1 antigen
detection over the course of the illness. The NS1 panel was used to
test microtiter ELISAs and RDTs. All tests were performed in
duplicates including the RDTs. Since each RDT represents a single
test the number of specimens in the table are including the duplicate
and is exactly twice as many specimens number as the ELISA tests.
Negative NS1 panel. The subpanels of DENV negatives and
challenge specimens were obtained from normal, healthy persons
living in dengue non-endemic areas and were negative for DENV
by RT-PCR and/or virus isolation, and IgM and IgG anti-DENV
negative. The challenge specimens included individuals with non-
DENV flavivirus illnesses, febrile illnesses of other etiologies, or
systemic conditions known to give rise to false positive results in
immunoassays (Table 4) and some were purchased from a
commercial source (SeraCare, West Bridgewater, MA).
Anti-DENV IgM panel. This panel consisted of 3 subpanels
with 527 patient serum specimens: 228 anti-DENV IgM positive
paired specimens from patients with dengue (Table 2) and 155
DENV IgM negative and 144 challenge specimens (Table 4). All
specimens were tested by the solid-phase anti-DENV IgM MAC-
ELISA used by CDC or AFRIMS [26,27]; a positive result by
either test was considered the reference value. All samples were
from paired specimens as previously defined for the NS1 panel.
Positive specimens were selected based on optical density (OD) in
Table 4. Characteristics of DENV negative specimens and challenge specimens for the evaluation of NS1 and anti-DENV IgM tests.*
NS1 IgM
America Asia Total America Asia Total
Negatives
Anti-DENV IgM and RT-PCR negative* 89 57 146 86 69 155
Systemic conditions
Rheumatoid Arthritis 10 9
Systemic Lupus Erythematosus 2 2
Total 12 12 11 11
Challenge Panel**
Febrile illnesses
IgG anti Lyme positive 10 10
IgM anti Hantavirus positive 6 9
IgM-IgG anti Hantavirus positive 1 1
IgG anti Hantavirus positive 1 2
Chikungunya 10
Scrub typhus 12
Leptospirosis 12 7
Malaria 30
Total 18 0 18 34 59 93
Related flavivirus
IgM anti West Nile positive 10 10
IgM anti Yellow Fever positive 3 3
IgG anti Yellow Fever positive 2 4
Flavivirus 1 4 10
IgM-IgG anti St Louis Encephalitis positive 3
IgG anti St Louis Encephalitis positive 1
Remote dengue (anti-DENV IgG positive) 2
Total 22 0 22 18 13 31
Other
Pregnancy 10 10
Subtotal Challenge Panel 141 57 149 151
Total 198 300
NS1 = non-structural protein 1, DENV = dengue virus.
*specimens from persons living in dengue non-endemic areas and negative for IgM and IgG antibody and reverse transcriptase polymerase chain reaction (RT-PCR) to
dengue virus (DENV).
**specimens from systemic conditions, other febrile illnesses, related flavivirus infections and past DENV infections.
doi:10.1371/journal.pntd.0003171.t004
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the respective tests, and weighted towards low and medium ODs
to increase the panel’s power to evaluate test sensitivity.
Anti-DENV IgM negative panel. DENV IgM negative
specimens were obtained from healthy individuals living in dengue
non-endemic areas and were negative for DENV RNA and/or
virus isolation, and IgM and IgG anti-DENV. Challenge
specimens were obtained from patients with febrile illness of other
etiologies, non-DENV flavivirus illnesses or systemic conditions
known to give rise to false positive results in immunoassays
(Table 4). Challenge specimens were solid-phase anti-DENV IgM
negative and some were purchased from a commercial source
(SeraCare, West Bridgewater, MA).
Statistical Analysis
Sensitivity and specificity were assessed against reference test by
analyte evaluated (NS1 or IgM). Kappa is a measure of the degree of
non-random agreement between observers or measurements of the
same categorical variable. Agreement is considered as good if kappa
is between 0.60 and 0.80, and very good if greater than 0.80.
The McNemar paired test was used to compare the difference
of agreement between operators. Proportions were compared
using the chi-square test or the Fischer exact test, whichever was
appropriate. Confidence intervals were set at 95% (CI95). P-values
lower than 0.05 were considered as statistically significant. The
statistical program used was STATA (version 11, Stata Corp.).
Results
DENV NS1 Microplate ELISAs
The sensitivities of the NS1 ELISAs in specimens from dengue
patients during the acute phase of illness ranged from 60–75%
(Table 5). Based on the overall results, test performance in order of
most sensitive to least sensitive was: Panbio E, Standard
Diagnostics and BioRad Platelia.
When specimens collected at DPO 6–14 were tested, the test
with the highest positive rate was Standard Diagnostics 31% (CI95
21–40 p=,.001) and the lowest positive rate was Panbio E 19%
(CI95 11–27; p,.001), (Table 5). All of these rates were statistically
different from those observed in the acute phase specimens (DPO
0–5) and were statistically different between tests.
Analysis by primary versus secondary DENV infection showed
that sensitivity was significantly affected for all tests. For persons
with a primary DENV infection, the test with the highest
sensitivity was Standard Diagnostics 75% (CI95 62–88), and the
least sensitive was Bio-Rad Platelia 60% (CI95 46–75); these results
were significantly higher than observed among dengue cases with
secondary infections: Standard Diagnostics 46% (CI95 38–54;
p = .001), BioRad Platelia 42% (CI95 34–50; p = .03). This analysis
included both acute and convalescent specimens (Table 5 and 6).
The specificity of these kits, determined with the DENV
negative and challenge specimen panels, is shown in Figure 1 and
ranged from 71–80%. Few specimens gave a false positive result in
the challenge panel; rheumatoid factor (RF) caused a false positive
result in 78% and 11% of the Panbio E and BioRad Platelia NS1
ELISA, respectively and positive specimens for YFV and non-
DENV flavivirus infections were reactive in the Panbio NS1
ELISA (Figure 1).
DENV NS1 RDTs
The sensitivities of NS1 RDTs in the acute phase specimens
(DPO 0–5) ranged from 40 to 59%: Panbio 60% (CI95 54–67) was
most sensitive and CTK Biotech 40% (CI95 31–49) the least
(Table 5). Among specimens collected in the convalescent phase of
dengue (DPO 6–14), the highest test positive rate was for the SD
BIOLINE Dengue Duo 59% (CI95 51–66); and the lowest test
positive was the Panbio 12% (CI95 7–17); With the exception of
SD BIOLINE Dengue Duo RDT, all of these were lower than the
rates observed in the acute phase specimens.
Analysis by primary versus secondary DENV infection showed
that most of the tests performed best among specimens from
patients with primary infections: SD BIOLINE Dengue Duo 71%,
(CI95 60–81) vs. 55% (CI95 50–61), (p = .016); Bio–Rad RDT 59%
(CI95 48–70) vs. 31% (CI95 25–36), (p,.001); CTK Biotech 47%
(CI95 36–59) vs. 21% (CI95 16–27), (p,.001), and Panbio 38%
(CI95 28–49) vs. 38% (CI95 32–43) (p = .915) (Table 5).
All four RDTs had similar specificities in the DENV negative
specimens (76–80%) (Figure 2). Against the challenge specimens,
the CTK Biotech test had reactivity against RF and the SD
BIOLINE Dengue Duo and Panbio tests had reactivity against
Hantavirus. All the NS1 RDTs had very good agreement between
operators with kappa values ranging from 0.84–0.99 (Table 7).
Anti-DENV IgM ELISA
Only Venture E submitted a test kit for evaluation which
showed an overall sensitivity of 96% (CI95 94–99). Comparison of
acute versus convalescent specimens demonstrated 98% (CI95 95–
100) sensitivity in acute phase specimens and 97% (CI95 94–100)
sensitivity in convalescent specimens. When analyzed according to
DENV infection status, the sensitivity was 97% (CI95 92–100) in
primary infections compared to 96% (CI95 94–99) in secondary
DENV infections (Table 6). The overall specificity was 84% (CI95
80–89) against the DENV negative panel. False positives reactions
were observed against other flavivirus infections - St Louis
Encephalitis virus (SLEV), Japanese Encephalitis virus (JEV) and
West Nile virus (WNV), as well as Chikungunya virus (CHIKV)
and Hantavirus. False positives rates were also observed for
malaria, leptospirosis and scrub typhus (Figure 3).
Anti-DENV IgM RDTs
The overall sensitivities of the IgM RDTs ranged from 52–95%.
In the acute phase panel, the most sensitive test was Orgenics 95%
(CI95 90–99), and the least sensitive was CTK Biotech 46% (CI95
36–55) (Table 6). In the convalescent panel sensitivities were
higher than those observed in the acute panel for the following
tests: CTK Biotech = 53% (CI95 48–59; p = .155) and SD
BIOLINE Dengue Duo IgM=98% (CI95 96–100; p = .002).
The following tests had lower sensitivities in the convalescent panel
when compared to the acute panel: Orgenics 82% (CI95 78–87;
p,.001) and Abon 56% (CI95 51–61; p = .227).
When evaluated based on DENV infection status, the SD
BIOLINE Dengue Duo had a sensitivity of 96% (CI95 91–100) in
primary infections compared to 84% (CI95 80–88) for secondary
infections (p= .009) and the Abon test had a sensitivity of 75% (CI95
65–86) for primary infections compared to 55% (CI95 50–60) for
secondary infections (p= .002). RDTs with statistically significant
increase in sensitivity in secondary infections, included: Orgenics
84% (CI95 76–93) compared to 97% (CI95 96–99) (p,.001) and
CTK Biotech 30% (CI95 19–41) compared to 55% (CI95 50–60)
(p=,.001) for primary and secondary, respectively (Table 6).
The overall specificity of these RDTs ranged from 86–92%,
with the highest false positive rate in the CTK Biotech test for RF
and systemic lupus erythematosus (Figure 4). The kappa values for
reader-to-reader variability ranged from 0.76–0.99 (Table 7).
Discussion
This laboratory-based, analytic evaluation of commercially
available dengue diagnostic tests for NS1antigen and anti-DENV
Evaluation of Commercial Dengue Diagnostic Tests
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Table 6. Sensitivity of anti-DENV IgM compared to IgM reference test in acute and convalescent samples.
Acute Convalescent
Tests Positive Total n=56 Sensitivity* (CI95) Positive Total n=168 Sensitivity* (CI95)
IgM ELISA Venture 55 56 98% (95–100) 160 165" 97% (94–100)
RT Abon 67 n= 112 107" 63% (53–72) 187 n = 336 334" 56% (51–61)
CTK 51 112 46% (36–55) 178 334" 53% (48–59)
Orgenic 100 112 95% (90–99) 250 255" 82% (78–87)
SD duo IgM 106 112 89% (84–95) 210 255" 98% (96–100)
Primary Secondary
Tests Positive Total n=35 Sensitivity* (CI95) Positive Total n=193 Sensitivity* (CI95)
IgM ELISA Venture 34 35 97% (92–100) 184 191" 96% (94–99)
RT Abon 49 N= 70" 65" 75% (65–86) 212 N=386" 386 55% (50–60)
CTK 21 70 30% (19–41) 214 386 55% (50–60)
Orgenic 59 70 84% (76–93) 298 306" 97% (96–99)
SD duo IgM 67 70 96% (91–100) 256 306" 84% (80–88)
Sensitivity of dengue anti-DENV IgM compared to IgM reference test in primary and secondary DENV infection status.
*Comparison to anti-DENV IgM reference positive samples.
"Number of samples tested differed to total number due to either duplicates for RDTs, invalid test or equivocal result.
Acute is days post onset of fever (DPO) of 0–5 days, Convalescent is DPO=6–14.
Primary = 1 DENV infection, Secondary $2 DENV infections.
CI95 = 95% confidence interval.
doi:10.1371/journal.pntd.0003171.t006
Table 5. Sensitivity of DENV NS1 antigen compared to RT-PCR and/or virus isolation in acute and positive rate of the convalescent
specimens.
Acute Convalescent
Tests Positive Total n =107 Sensitivity* (CI95) Positive Total n=85 Sensitivity
" (CI95)
NS1 ELISA Bio-Rad 64 106" 60% (51–70) 24 83" 29% (19–39)
Panbio 78 104" 75% (67–83) 16 84" 19% (11–27)
SD 74 105" 70% (62–79) 26 85 31% (21–40)
RT Bio-Rad 104 n= 214 199" 52% (45–59) 32 n= 170 170 19% (13–25)
CTK 50 125" 40% (31–49) 33 170 19% (13–35)
Panbio 119 197" 60% (54–67) 21 170 12% (7–17)
SD Duo NS1 115 195" 59% (52–66) 100 170 59% (51–66)
Primary Secondary
Tests Positive Total n =45 Sensitivity* (CI95) Positive Total n=147 Sensitivity
" (CI95)
NS1 ELISA Bio-Rad 26 43" 60% (46–75) 62 147 42% (34–50)
Panbio 28 43" 65% (51–79) 66 146" 45% (37–53)
SD 33 44" 75% (62–88) 67 147 46% (38–54)
RT Bio-Rad 46 n= 90" 78" 59% (48–70) 90 n= 294" 293" 31%(25–36)
CTK 37 78" 47% (36–59) 46 218" 21% (16–27)
Panbio 30 78" 38% (28–49) 110 291" 38% (32–43)
SD duo NS1 55 78" 71% (60–81) 160 289" 55% (50–61)
Sensitivity of dengue NS1 antigen in primary and secondary DENV infection status.
*Comparison to RT-PCR DENV positive samples,
"Comparison to IgM seroconversion
"Number of samples tested differed to total number due to either duplicates for RDTs, invalid test or equivocal result.
Acute is days post onset of fever (DPO) of 0–5 days, convalescent is DPO= 6–14.
Primary = 1 DENV infection, Secondary $2 DENV infections.
CI95 = 95% confidence interval.
doi:10.1371/journal.pntd.0003171.t005
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IgM used a sufficient number of specimens to yield confidence
intervals of +5% around the point estimates of test sensitivity and
specificity [28]. Test sensitivity was determined in the acute and
convalescent phases of dengue illness where a reference test was
available (i.e., IgM anti-DENV) and in patients with primary and
secondary DENV infections. The goal of this study was to provide
reliable information on product performance to those performing
dengue diagnostics, as well as to the test manufacturers.
DENV NS1 antigen is present in the acute phase of dengue with
peak detection at DPO 3 followed by a rapid decline through the
convalescent phase (DPO.5) [29]. The 3 microplate ELISAs
evaluated in our study showed similar findings. During the
convalescent phase of illness, previous studies have shown test
positivity ranging from 22% to 40% among dengue cases defined
by a positive IgM anti-DENV seroconversion between acute and
convalescent specimens [12,30,31], a finding similar to ours.
Since NS1 is a viral antigen, the only available reference
standard has been the presence of DENV as determined by RT-
PCR. However, viral antigens may persist in serum longer than
viral nucleic acid detected by molecular amplification or virus
detected by cell culture. Thus, the interpretation of NS1 ELISA
and RDT results obtained from specimens in the convalescent
panel is not straightforward. All specimens in our panel were anti-
DENV IgM positive but negative for DENV by RT-PCR or virus
isolation. By strict definition, we were not able to determine the
sensitivity of these tests in convalescent phase specimens because
there was no reference standard for comparison. One interpreta-
tion is these are false-positive results since the specimens were
DENV RNA negative. However, it has been shown in longitudinal
studies of dengue patients that NS1 antigen remains positive after
DENV RNA amplicons disappear [12,30,31] probably because of
longer half-life of NS1 protein. The 19–30% test positivity in the
convalescent panel could represent detection of residual NS1
antigen although some of these could also be false positive results.
Until a protein based reference standard for NS1 is developed or a
confirmatory test for NS1 test-reactivity is developed, study designs
that follow patients sequentially during their illness are required to
determine the diagnostic utility of this test in the early convalescent
phase of dengue.
Our study showed higher sensitivity in primary than secondary
DENV infections for both NS1 ELISAs and RDTs, with the
exception of the Panbio RDT which had equal sensitivity
(Table 5). The analysis included specimens from both acute and
convalescent phase. This difference in NS1 detection has been
Figure 1. False positive rate of DENV NS1 ELISAs in DENV negatives and challenge panel specimens.
doi:10.1371/journal.pntd.0003171.g001
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observed previously [12,30,31] and may be explained by presence
of anti-NS1 IgG, which occurs most frequently in secondary
DENV infections, and may mask antigen detection by immune
complex formation. Higher NS1 ELISA sensitivity has been
reported for primary DENV infections not containing NS1
immune complexes compared to secondary DENV infections
with complexes.
Although generally the NS1 RDTs had reduced sensitivities
compared to the NS1 ELISAs, they had similar specificities, and
the RDT’s good agreement (..80) between operators. However,
there were still differences noted between laboratories as observed
previously in the evaluation of the IgM anti-DENV RDTs [17].
As might be expected, there were significant differences in
sensitivity between acute and convalescent specimens for the IgM
anti-DENV RDTs because anti-DENV IgM peaks at DPO 10,
except for the Abon RDT which had essentially similar sensitivity
in the both periods. Anti-DENV IgM titers have been shown to be
higher in primary compared to secondary infections, with as many
as 20% of dengue cases with secondary infection having
undetectable levels of anti-DENV IgM in convalescent specimens
[16]. When examined by DENV infection status, the present
evaluation showed that two of the tests, CTK Biotech and
Orgenics, had significantly higher sensitivity in secondary com-
pared to primary infections.
The utility of using both IgM anti-DENV and NS1 antigen for
dengue diagnostic testing has been evaluated in recent studies,
suggesting an added diagnostic benefit to this testing combination.
[14,32] Measuring both analytes during the early course of the
illness (DPO 0–8) expands the diagnostic window of opportunity
since NS1 detection is best detected during DPO 0–5 and anti-
DENV IgM is best detected during DPO 5–14.
This study had several limitations as well as strengths. Test
performance was compared to the evaluation panels, which were
only characterized by the two reference laboratories using the
reference methods. Additionally, the NS1 and IgM anti-DENV
test sensitivity could not be evaluated by DENV serotype because
of an insufficient number of specimens to allow for this sub-
analysis. In addition, the small number of samples in some of the
challenge panel categories did not provide strong point and
confidence interval estimates similar to those derived for the
DENV positive panels, and only identified potential issues. Lastly,
the infectious agents represented in the challenge panels may not
Figure 2. False positive rate DENV NS1 rapid diagnostic tests in
DENV negatives and challenge panel specimens.
doi:10.1371/journal.pntd.0003171.g002
Table 7. Test agreement between operators.
Detection type Tests* N Agreement Kappa
Value CI95 p**
NS1 Bio-Rad RT 661 99% 0.99 0.97–1.00 1.000
CTK RTNS1 539 98% 0.94 0.91–0.97 0.388
Panbio RT 660 97% 0.93 0.91–0.96 0.019
SD RT duo 654 92% 0.84 0.80–0.88 0.322
IgM Abon RT 917 91% 0.79 0.74–0.83 0.590
CTK RTIgM 887 94% 0.88 0.84–0.91 0.322
Orgenics RT 802 88% 0.76 0.71–0.80 0.417
SD RT duo 805 91% 0.81 0.77–0.85 1.000
Each test (anti-DENV IgM rapid test (RT) and the DENV NS1 antigen RT) was read and recorded independently by two operators. The agreement between the operators
was reflected as kappa values.
*Each test was read and recorded independently by two operators.
**McNemar test.
doi:10.1371/journal.pntd.0003171.t007
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be of epidemiologic importance in all populations where dengue
occurs. The convalescent specimens used for the NS1 evaluation
were not characterized with the same reference tests as the acute
specimens and no further testing was performed to determine if a
positive result was a true or false positive. The strength of the study
was that a high proportion of specimens in the panels were from
persons with secondary DENV infections which, reflects the
situation in most dengue endemic countries. In addition, most tests
tended to perform better for primary DENV infections, which would
mitigate any concerns about test performance in patients with this
infection status (e.g., travelers from non-endemic countries).
Results from this evaluation have been provided to the
manufacturers and WHO member states and provide benchmarks
for the evaluation, procurement and use of dengue diagnostic tests
at the country or regional level. This study indicates that most of
the NS1 microplate ELISAs performed adequately for routine,
clinical diagnostic use in dengue endemic countries. However, the
clinical and epidemiologic consequences of the lower sensitivity of
NS1 tests compared to DENV RNA detection should be
considered when using these tests for routine use.
The microplate anti-DENV IgM ELISA continues to show
good performance and this evaluation indicates that the one test
evaluated had good sensitivity in the early phase of the illness, an
area that has been problematic in the past. Whether these tests
should be combined with NS1 microplate ELISAs for routine
testing or in a testing algorithm based on when a patient presents
for clinical care, needs to be evaluated in large-scale clinical
studies.
Unfortunately the RDTs for both NS1 and anti-DENV IgM
continue to have relatively poor performance profiles; a problem
for resource poor countries. Since the combination NS1/anti-
DENV IgM RDTs was only evaluated for each analyte
individually, no statement can be made regarding its performance
as a combination test. This study did not address the issue of how
RDTs, with their lower sensitivity, might be used in resource poor
areas. Even with their lower sensitivity but comparable specificities
compared the ELISAs, they could be used to identify dengue
outbreaks. However, large studies are needed to determine the
most effective way to use them for case management, disease
Figure 3. False positive rate of anti-DENV IgM ELISA (Venture
Technologies Sdn Bhd) in DENV negatives and challenge panel
specimens.
doi:10.1371/journal.pntd.0003171.g003
Figure 4. False positive rate of anti-DENV IgM rapid diagnostic
tests in DENV negatives and challenge panel specimens.
doi:10.1371/journal.pntd.0003171.g004
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surveillance or whether their present shortcomings can be
overcome by a combination testing algorithm.
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